JP Morgan Chase
ALT icon

JP Morgan Chase’s Altimmune ALT Stock Holding History

JP Morgan Chase’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$387 – 7369
2025
Q2 		$387 Buy
+100
New +$541 ﹤0.01% 6719
2022
Q4 		– Sell
-83,100
Closed -$1.06M – 6514
2022
Q3 		$1.06M Buy
+83,100
New +$1.23M ﹤0.01% 3944

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase's ALT Position: Q1 2026 in Review

JP Morgan Chase increased its Altimmune (ALT) stake by 22% in Q1 2026, buying an estimated $97.5K and bringing the position to 127,498 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #5192.

JP Morgan Chase first reported a position in ALT in Q4 2016 and has held it in 27 quarters since. The position peaked at $8.31M in Q3 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • JP Morgan Chase held 127,498 shares of Altimmune worth $367K as of Q1 2026.
  • JP Morgan Chase bought 22,966 Altimmune shares in Q1 2026, an estimated $97.5K.
  • Altimmune made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5192 holding.
  • JP Morgan Chase first reported a position in Altimmune in Q4 2016 and has held it in 27 quarters since.
  • JP Morgan Chase's Altimmune position peaked at $8.31M in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.